BSX · 10-Q · 2026Q2

BOSTON SCIENTIFIC CORP

Filed 2026-08-03 · Healthcare · View original filing on EDGAR

Ranked Events

• Regulatory RiskImportance 75 · Surprise 60
  The U.S. Federal Trade Commission is reviewing Boston Scientific’s proposed $14.5 billion acquisition of Penumbra. On March 16, 2026, Boston Scientific and Penumbra each received a Second Request for additional…
• Acquisition / Partnership / DivestitureImportance 75 · Surprise 60
  Boston Scientific agreed on January 15, 2026 to acquire 100% of Penumbra for approximately $14.5 billion, or $374 per share. Penumbra stockholders approved the transaction on May 6, 2026, but the companies received an…
• Income Tax Rate ChangesImportance 71 · Surprise 82
  The reported tax rate was 14.6% in the second quarter of 2026 versus 15.5% in the second quarter of 2025, while the continuing-operations rate was 17.3% versus 18.4%. For the first six months, the reported rate…
• Operating Cash Flow and CapexImportance 69 · Surprise 64
  Operating cash flow was $1.822 billion in the first six months of 2026, broadly unchanged from $1.827 billion in the prior-year period. Higher sales and operating income were offset by increased employee-related and…
• Liquidity and Cash PositionImportance 64 · Surprise 42
  Boston Scientific held $539 million of unrestricted cash and cash equivalents at June 30, 2026, including $130 million in money-market funds and time deposits and $409 million in bank accounts. The company entered a…
• Stock Repurchase ProgramImportance 64 · Surprise 42
  On February 18, 2026, the Board increased Boston Scientific’s common-stock repurchase authorization by $4.0 billion, raising total authorization to $5.0 billion. Under an accelerated share repurchase agreement with…
• Restructuring ChargesImportance 64 · Surprise 42
  Boston Scientific’s 2023 Restructuring Plan, expanded by up to $250 million in July 2025, has an estimated total pre-tax cost of approximately $700 million to $800 million. The program covers manufacturing-line…
• Gross Margin DriversImportance 54 · Surprise 40
  Gross profit increased to $3.848 billion in the second quarter of 2026 from $3.424 billion in the prior-year quarter and to $7.462 billion for the first six months from $6.633 billion. Gross margin expanded to 70.7%…
• Market Demand TrendsImportance 49 · Surprise 32
  Boston Scientific reported six-month 2026 organic sales growth of 8.1%, with Cardiovascular growing 9.4% organically and MedSurg growing 5.6%. Cardiovascular demand was supported by coronary therapies and…
• Operating Expense TrendsImportance 49 · Surprise 32
  Second-quarter SG&A expense increased $87 million, or 5%, to $1.803 billion, while six-month SG&A increased $271 million, or 8%, to $3.583 billion. SG&A declined as a percentage of sales by 80 basis points to 33.1% in…
• Revenue Performance and MixImportance 49 · Surprise 32
  Second-quarter 2026 net sales increased 7.5% year over year to $5.442 billion, while six-month sales increased 9.5% to $10.646 billion. Organic growth was 7.0% in the quarter and 8.1% for the first six months after…
• Trade Policy and TariffsImportance 37 · Surprise 42
  Boston Scientific cites significant uncertainty in global trade policies, including changing tariff rates, delayed tariff impositions and potential reciprocal restrictions by the U.S. or other governments. The company…
• Liquidity and Capital PositionImportance 31 · Surprise 6
  Boston Scientific expects cash, operating cash generation, capital-market access and credit facilities to fund operations, infrastructure investment, legal liabilities, taxes, debt service, repayment and possible…
• Geographic Market CommentaryImportance 31 · Surprise 32
  China was a specific area of weakness in Boston Scientific’s Urology business during the second quarter and first six months of 2026. The company attributed underperformance in its stone franchise to volume-based…
• Competition and Market ShareImportance 23 · Surprise 24
  Boston Scientific said increased competition in its Electrophysiology business unit affected Cardiovascular sales in both the second quarter and first six months of 2026. The company also reported a deceleration in…
• Products and TechnologyImportance 23 · Surprise 24
  Endoscopy growth was led by the biliary franchise, particularly the AXIOS™ Stent and Delivery System, along with the core GI franchise. Neuromodulation demand was driven by the Intracept™ Intraosseous Nerve Ablation…

Revenue by Product (in millions)

Revenue by Geography (in millions)